公开(公告)号：US10660875B1

公开(公告)日：2020-05-26

申请号：US16738261

申请日：2020-01-09

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Seth Cabot Hopkins ,  Kenneth Stephen Koblan ,  John R. Snoonian ,  Harold Scott Wilkinson

IPC: A61K31/40 ,  A61P25/24

Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.

公开(公告)号：US10556890B2

公开(公告)日：2020-02-11

申请号：US15851836

申请日：2017-12-22

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： John Emmerson Campbell ,  Una Campbell ,  Taleen G. Hanania ,  Liming Shao

IPC: C07D409/04 ,  C07D409/14 ,  C07D491/048 ,  C07D495/04 ,  C07D405/04

Abstract: Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

公开(公告)号：US20190389845A1

公开(公告)日：2019-12-26

申请号：US16403698

申请日：2019-05-06

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Linghong Xie ,  Philip Glyn JONES ,  Kerry L. SPEAR ,  Noel Aaron POWELL ,  Taleen G. HANANIA ,  Vadim ALEXANDROV

IPC: C07D405/04 ,  C07D405/14 ,  C07D413/14 ,  C07D493/04 ,  C07D413/04

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

公开(公告)号：US20190194163A1

公开(公告)日：2019-06-27

申请号：US16322278

申请日：2016-08-04

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Michele L.R. HEFFERNAN ,  Larry Wendell HARDY ,  Scott P. BROWN ,  Lee W. HERMAN

IPC: C07D401/08 ,  C07D405/06 ,  C07D401/06 ,  C07D401/14 ,  C07D207/12 ,  C07D295/096 ,  C07D295/027 ,  C07D311/22 ,  C07D471/04 ,  C07D235/12 ,  C07D237/14 ,  C07D217/24 ,  C07D295/073 ,  C07D295/108 ,  C07D275/04 ,  C07D311/08 ,  C07D307/83 ,  C07D491/048 ,  C07D277/66 ,  C07D401/12 ,  C07D211/44 ,  C07D211/58 ,  C07D265/30 ,  C07D413/06 ,  C07D241/04 ,  C07D223/08 ,  C07D267/10 ,  C07D243/08 ,  C07D413/08 ,  C07D471/08 ,  C07D487/10 ,  C07D471/10 ,  C07D491/107

CPC classification number: C07D401/08 ,  A61P25/18 ,  A61P25/28 ,  C07D207/12 ,  C07D207/36 ,  C07D211/42 ,  C07D211/44 ,  C07D211/58 ,  C07D213/81 ,  C07D217/24 ,  C07D221/20 ,  C07D223/08 ,  C07D235/12 ,  C07D237/14 ,  C07D241/04 ,  C07D243/08 ,  C07D249/12 ,  C07D265/30 ,  C07D267/10 ,  C07D275/04 ,  C07D277/66 ,  C07D295/027 ,  C07D295/073 ,  C07D295/088 ,  C07D295/096 ,  C07D295/104 ,  C07D295/108 ,  C07D307/83 ,  C07D311/08 ,  C07D311/22 ,  C07D311/58 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D405/06 ,  C07D405/12 ,  C07D413/06 ,  C07D413/08 ,  C07D417/04 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/10 ,  C07D491/048 ,  C07D491/107 ,  C07D491/20 ,  C07D513/04

Abstract: Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

公开(公告)号：US10285953B2

公开(公告)日：2019-05-14

申请号：US15225992

申请日：2016-08-02

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Nathan John Bryson ,  Anthony John Giovinazzo ,  Scott David Barnhart ,  Michael Clinton Koons

IPC: A61K9/70 ,  A61F13/00 ,  A61K31/435 ,  A61K31/473 ,  A61K31/485 ,  A61K31/4415 ,  A61K47/02 ,  A61K9/00 ,  A61K47/14 ,  A61K47/38 ,  A61K31/4045 ,  A61K45/06 ,  A61K31/381 ,  A61K31/428 ,  A61K31/48 ,  A61K31/4985 ,  A61K31/506 ,  A61J1/03 ,  A61J7/00 ,  B29C39/18 ,  B65D65/38 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/22 ,  A61K47/36 ,  B29C39/38 ,  B29C43/30 ,  B29C43/52 ,  B29C65/70 ,  B29C65/00 ,  A61K9/24 ,  B29K1/00 ,  B29L31/00 ,  B29L7/00 ,  B29L9/00

Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

公开(公告)号：US10085968B2

公开(公告)日：2018-10-02

申请号：US14950834

申请日：2015-11-24

Applicant: Sunovion Pharmaceuticals, Inc. ,  PGI Drug Discovery LLC

Inventor： Liming Shao ,  John Emmerson Campbell ,  Michael Charles Hewitt ,  Una Campbell ,  Taleen G. Hanania

IPC: C07D233/00 ,  C07D403/02 ,  C07D403/14 ,  C07D231/00 ,  C07D487/02 ,  C07D487/00 ,  C07D405/00 ,  C07D409/00 ,  C07D495/02 ,  A61K31/415 ,  A61K31/40 ,  C07D277/22 ,  A61K31/381 ,  C07D277/60 ,  C07D333/54 ,  C07D333/76 ,  C07D333/78 ,  C07D495/04 ,  C07D495/20 ,  A61K31/435 ,  A61K31/55 ,  A61K45/06

Abstract: Provided herein are multicyclic compounds of formula (IVa), shown below, wherein R1, R2, R3, R4, R5, R6, R7, m, and n are defined herein elsewhere, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

公开(公告)号：US10076503B2

公开(公告)日：2018-09-18

申请号：US15310351

申请日：2015-05-12

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Antony D. Loebel ,  Kenneth S. Koblan

IPC: A61K31/135 ,  A61K9/00

CPC classification number: A61K31/135 ,  A61K9/0053 ,  A61K9/4858

Abstract: Dosage forms and treatment regimens employing dasotraline for treating Attention Deficit Hyperactivity Disorder (ADHD) are disclosed. The compositions described herein exhibit no abuse potential.

公开(公告)号：US20180148407A1

公开(公告)日：2018-05-31

申请号：US15817760

申请日：2017-11-20

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Liming Shao ,  Fengjiang Wang ,  Scott C. Malcolm ,  Michael C. Hewitt

IPC: C07D209/44 ,  C07D209/52 ,  A61K31/4035 ,  C07D209/08

CPC classification number: C07D209/44 ,  A61K31/4035 ,  C07D209/08 ,  C07D209/52

Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

公开(公告)号：US09868718B2

公开(公告)日：2018-01-16

申请号：US14502532

申请日：2014-09-30

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Liming Shao ,  Fengjiang Wang ,  Scott Christopher Malcolm ,  Michael Charles Hewitt ,  Larry R. Bush ,  Jianguo Ma ,  Mark A. Varney ,  Una Campbell ,  Sharon Rae Engel ,  Larry Wendell Hardy ,  Patrick Koch ,  John E. Campbell

IPC: C07C13/28 ,  C07D333/20 ,  C07C211/17 ,  C07C211/29 ,  C07C211/40 ,  C07C215/42 ,  C07C215/44 ,  C07C217/52 ,  C07C217/74 ,  C07C323/32 ,  C07D207/06 ,  C07D207/08 ,  C07D211/14 ,  C07D265/14 ,  C07D277/28 ,  C07D295/06 ,  C07D307/52 ,  C07D317/58 ,  C07D317/72 ,  C07D319/06 ,  C07D491/056 ,  C07D211/16

CPC classification number: C07D333/20 ,  C07C211/17 ,  C07C211/29 ,  C07C211/40 ,  C07C215/42 ,  C07C215/44 ,  C07C217/52 ,  C07C217/74 ,  C07C323/32 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/10 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2602/08 ,  C07D207/06 ,  C07D207/08 ,  C07D211/14 ,  C07D211/16 ,  C07D265/14 ,  C07D277/28 ,  C07D295/06 ,  C07D307/52 ,  C07D317/58 ,  C07D317/72 ,  C07D319/06 ,  C07D491/056

Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

公开(公告)号：US09834564B2

公开(公告)日：2017-12-05

申请号：US14627355

申请日：2015-02-20

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： John Emmerson Campbell ,  Michael Charles Hewitt ,  Philip Jones ,  Linghong Xie

IPC: A61K31/4709 ,  C07D215/12 ,  C07D498/06 ,  C07D401/06 ,  C07D403/06 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D491/056 ,  C07D498/14 ,  C07D519/00 ,  C07D401/14 ,  C07D405/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/06 ,  C07D417/06 ,  C07D498/04 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5383 ,  C07D233/58 ,  C07D471/06

CPC classification number: C07D498/06 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5383 ,  C07D233/58 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D405/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/06 ,  C07D417/06 ,  C07D471/04 ,  C07D471/06 ,  C07D471/14 ,  C07D487/04 ,  C07D491/056 ,  C07D498/04 ,  C07D498/14 ,  C07D519/00

Abstract: Provided herein are Cyclic Nucleotide Phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.